Perspective: Rethinking Therapeutic Strategies in Oncology
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Immuno-oncology has revolutionized cancer care, drug development, the design of clinical trials, standard treatment paradigms, and the evaluation of response to therapy. These are all areas, however, that have not fully incorporated principles of tumor immunology. Insufficient emphasis is put on the effect drugs have on the immune system, and specifically, the impact that multiple lines of therapy can have on the functioning of the immune system, hindering a robust anti-tumor immune response. A paradigm shift in how we approach the development of novel immunotherapeutic agents is necessary to facilitate the effective improvements in patient outcomes.
References
1.
Birchard K, Hoang J, Herndon Jr J, Patz Jr E
. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer. 2009; 115(3):581-6.
DOI: 10.1002/cncr.24060.
View
2.
Shaked Y
. The pro-tumorigenic host response to cancer therapies. Nat Rev Cancer. 2019; 19(12):667-685.
DOI: 10.1038/s41568-019-0209-6.
View
3.
Einloth K, Gayfield S, McMaster T, Didier A, Dworkin L, Creeden J
. The application, safety, and future of immune cell therapies and prognosis in different malignancies. Bioimpacts. 2023; 13(6):439-455.
PMC: 10676524.
DOI: 10.34172/bi.2023.27521.
View
4.
Boyero L, Sanchez-Gastaldo A, Alonso M, Noguera-Ucles J, Molina-Pinelo S, Bernabe-Caro R
. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers (Basel). 2020; 12(12).
PMC: 7763130.
DOI: 10.3390/cancers12123729.
View
5.
Matson V, Chervin C, Gajewski T
. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2020; 160(2):600-613.
PMC: 8409239.
DOI: 10.1053/j.gastro.2020.11.041.
View